Editorial Team

Eduard Cristea

Health Technology Researcher & Publisher

MSc Health Informatics

Eduard Cristea is the publisher and editor-in-chief of WeightLoss GLP-1. He has spent the last eight years analyzing direct-to-consumer health technology markets and built the WeightLoss GLP-1 100-point rubric used to score every program reviewed on this site. He sets the editorial standards, oversees the review desk, and signs off on every published methodology update.

Areas of expertise

• Direct-to-consumer telehealth market analysis
• Pharmacy compounding regulation (503A and 503B)
• GLP-1 pricing and savings card mechanics
• Affiliate disclosure and FTC compliance

Recent publications

• Compounded GLP-1 pricing: 2026 market map (WLG, May 2026)
• 503A vs 503B: what consumers actually need to know (WLG, Apr 2026)
• How online weight-loss clinics market — and where they cut corners (WLG, Mar 2026)

Dr. A. Goher, MD

Medical Reviewer — Internal Medicine

MD, board-certified Internal Medicine

Dr. Goher reviews every clinically-relevant page on WeightLoss GLP-1 for accuracy and safety. Her review covers dosing ladders, contraindications, interaction warnings, lab requirements, and the framing of side-effect data. She has practiced internal medicine for fourteen years and has prescribed GLP-1 receptor agonists since 2017.

Areas of expertise

• GLP-1 receptor agonist therapy
• Cardiometabolic risk reduction
• Pre-diabetes and Type 2 diabetes management
• Outpatient weight management

Dr. J. Bottoni, MD

Senior Clinical Reviewer — Endocrinology

MD, fellowship-trained in Endocrinology, Diabetes & Metabolism

Dr. Bottoni is a fellowship-trained endocrinologist who reviews WeightLoss GLP-1 content on hormonal mechanisms, off-target effects, and long-term metabolic outcomes. He authored the site's primer on how GLP-1, GIP, and glucagon receptor agonism differ across the current and pipeline drug classes.

Areas of expertise

• Pituitary and adrenal disorders
• Insulin resistance and metabolic syndrome
• Pipeline incretin therapies (triple agonists, oral GLP-1s)
• Bone-density and lean-mass considerations on GLP-1 therapy

Dr. Richard Allen, DO

Clinical Reviewer — Family Medicine & Obesity Medicine

DO, ABOM Diplomate (American Board of Obesity Medicine)

Dr. Allen is an ABOM-certified obesity medicine physician with twelve years of ambulatory practice. He reviews WeightLoss GLP-1 content on titration, side-effect management, and patient communication. He has supervised compounded GLP-1 protocols since 2022 and writes the site's clinical playbook chapters.

Areas of expertise

• Obesity medicine and behavioral health integration
• Compounded GLP-1 titration protocols
• Side-effect mitigation (nausea, GI tolerance, fatigue)
• Off-ramping and maintenance dosing

Dr. Samuel Lora, MD

Pharmacology Reviewer — Compounding & Sterile Preparations

MD, pharmacology-focused medical practice

Dr. Lora reviews WeightLoss GLP-1 content on compounded sterile preparations, USP <797> compliance, beyond-use dating, and the practical differences between 503A and 503B operations. He audits the site's pharmacy partner pages and the scam-checker rubric.

Areas of expertise

• 503A and 503B pharmacy compounding
• USP <797> sterile-compounding standards
• Drug stability and beyond-use dating
• Pharmacy verification (LegitScript, NABP, state boards)

Dr. Christian Bentley, MD

Clinical Reviewer — Preventive Cardiology

MD, preventive cardiology focus

Dr. Bentley reviews WeightLoss GLP-1 content on cardiovascular outcomes, the SELECT and SURMOUNT trials, blood-pressure changes on GLP-1 therapy, and lipid-panel monitoring. He audits the site's coverage of GLP-1s in patients with atherosclerotic cardiovascular disease.

Areas of expertise

• ASCVD primary and secondary prevention
• Cardiovascular outcomes in GLP-1 trials (SELECT, SURMOUNT)
• Blood-pressure and lipid management on incretin therapy
• Heart failure with preserved ejection fraction (HFpEF)